Some 35 neuromuscular disease experts, along with biotechnology and government representatives, will meet Friday and Saturday at the Westin La Paloma, Tucson, Arizona to develop a large-scale network to test potential treatments in muscular dystrophy, the Muscular Dystrophy Association (MDA) have announced.
The network, which could allow for centralized data collection and data sharing, is being developed in anticipation of an increased number of therapeutic trials for muscular dystrophy. Such a network could also be used to learn how to better manage medical complications of these diseases, including breathing and heart problems.
Initial emphasis will be on trials for Duchenne MD, a severe, childhood-onset form of the disease.
“MDA investigators are working hard to translate new findings in the lab into therapies that will benefit those served by MDA,” Director of Research Development Sharon Hesterlee said. “We want to make sure they have all the tools they need to accomplish these goals.”
Susan Iannaconne, a physician specializing in neuromuscular disease at the University of Texas Southwestern Medical Center at Dallas, and Richard Moxley, a physician specializing in neuromuscular disease at the University of Rochester (N.Y.) Medical Center, will co-chair the conference.
MDA is a voluntary health agency working to defeat more than 40 neuromuscular diseases through programs of worldwide research, comprehensive services, and far-reaching professional and public health education.